Iron absorption and oxidant stress during erythropoietin therapy in very low birth weight premature infants: a cohort study by James K Friel et al.
BioMed CentralBMC Pediatrics
ssOpen AcceResearch article
Iron absorption and oxidant stress during erythropoietin therapy in 
very low birth weight premature infants: a cohort study
James K Friel*1,2,3, Khalid Aziz3, Wayne L Andrews†3 and Robert E Serfass†4
Address: 1Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, R3T 2N2, Canada, 2Department of 
Biochemistry, Memorial University, St. John's, Newfoundland, A1B 3X9, Canada, 3Department of Pediatrics, Memorial University, St. John's, 
Newfoundland, A1B 3X9, Canada and 4Department of Preventive Medicine and Community Health, The University of Texas Medical Branch at 
Galveston, Galveston, Texas, 77555-1109, USA
Email: James K Friel* - frielj@ms.umanitoba.ca; Khalid Aziz - kaziz@mun.ca; Wayne L Andrews - wandrews@mun.ca; 
Robert E Serfass - reserfas@utmb.edu
* Corresponding author    †Equal contributors
Abstract
Background: Iron supplementation may be associated with oxidative stress particularly in
premature infants. Our purpose was to examine 1) early supplemental iron during treatment with
erythropoietin (EPO) and oxidative stress; 2) enhanced iron absorption during EPO in those infants
receiving human milk. Therefore, we determined the effect of erythropoietin plus supplemental
iron intakes (4 mg/kg/d) on antioxidant status and iron incorporation.
Methods: Ten very-low-birth-weight infants who were enterally fed and receiving either human
milk or formula were followed for 4 weeks during erythropoietin therapy; blood and urine were
collected at 3 times; baseline, 2 and 4 weeks later. Once oral feeds commenced the study protocol
was initiated. After baseline blood collection, a dose of Fe57 was administered. Two weeks later, a
dose of Fe58 was administered as ferrous chloride to determine the effect of human-milk or formula
on iron incorporation into RBCs.
Results: Infants started the study at 35 ± 13 days. Incorporation of isotope into RBCs did not differ
between formula fed for Fe57 (mean incorporation 8 ± 2.9 n = 3) compared to human-milk fed
infants (8.7 ± 5 n = 7) nor for Fe58 (6 ± 2.7 n = 3 vs. 8.6 ± 5 n = 7). Tissue damage measured by
malondialdehyde in plasma and F-2 – isoprostanes in urine, did not differ by feed or over time.
Neither ability to resist oxidative stress/nor RBC superoxide dismutase differed according to feed
or over time.
Conclusion: Data suggest that during erythropoietin therapy antioxidant defence in VLBW infants
are capable of dealing with early supplemental iron during treatment with EPO.
Background
Infant formulas (F) have been the prevalent feed for very
low birthweight (VLBW, < 1500 g birthweight) infants.
More recently, neonatal units have successfully imple-
mented human milk (HM) feeding programs with sup-
port groups so that human milk is now routinely fed to
the majority of these infants. Rates vary across Canada
from ~ 50% in St. John's NFLD to > 90 % in Victoria BC
(Derek Matthews, Wayne Andrews, personal communica-
tion). Human milk alone may not meet all the nutritional
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months of life. Therefore, human milk is supplemented
with appropriate nutrients [1,2]. Few studies [3,4] have
examined iron intakes in VLBW infants receiving human
milk. Therefore, the iron needs of this group are poorly
defined.
A prevalent condition in VLBW infants during the first
months of life is anemia. This "physiologic" anemia may
be compounded by non-physiologic mechanisms such as
red blood cell loss due to bleeding, hemolysis etc., and fre-
quent blood sampling for clinical purposes [5]. Because
the premature infant has a diminished erythropoietin
(EPO) response to anemia, the administration of exoge-
nous recombinant EPO has been proposed as a promising
therapy. Early trials with EPO alone, reported variable
results, which may have been due to limited availability of
iron for hemoglobin formation [6-8]. While iron is now
commonly provided with EPO, the amounts of iron sup-
plements provided with EPO are not consistent and range
from 0–12 mg/kg/d [6,9]. There is little experience with
iron administered at these levels in the early life of the
neonate and in only one of the trials with EPO (given intra-
venously as well as orally) has the safety of supplemental
intakes of iron been examined [9]. Further, 1) little data is
available on iron absorption in these infants 2) no distinc-
tion is made between breast-fed and formula fed infants
in terms of possible differences in iron absorption related
to the large amounts of iron provided as supplements dur-
ing EPO. If iron absorption is indeed greater in human
milk fed than formula-fed infants [10,11], then human
milk fed VLBW infants may be at increased risk for prob-
lems associated with iron excess, particularly production
of free radicals [12].
We used erythrocyte incorporation of an iron stable iso-
tope as a surrogate for iron absorption in the intestinal
tract (6, 9, 10). We assume that in identical conditions
prompt erythrocyte incorporation of iron would account
for the same percentage of newly absorbed iron by all
infants in the study.
Our hypotheses were: 1) intakes of early supplemental
iron during treatment with EPO would stress antioxidant
defenses and lead to oxidant damage 2) iron absorption
during EPO therapy plus iron supplements would be ele-
vated with HM feeding. This study was necessary as the
effect on oxidative stress during EPO therapy has not been
reported nor has the possible increase in absorption of
iron in human milk feeding been examined during EPO.
We did not find any effect of HM on iron absorption nor
an increase in oxidative stress during EPO.
Methods
The study included 10 VLBW infants who received EPO
plus iron (2–4 mg/kg/d) as part of their normal clinical
care. The study protocol was approved by the Memorial
University Ethics Committee and informed written per-
mission was obtained from parents/guardians. The base-
line period was that time before the administration of
EPO and iron isotopes. EPO treatment began when
infants were tolerating 75% of feeds (non-iron fortified
formula or human milk) by the enteral route. On two sep-
arate occasions, before commencement of EPO treatment,
and again after 2 weeks of EPO treatment stable non-radi-
oactive isotopes of iron (57Fe, 58Fe) were administered
enterally. At baseline and again at 2 and 4 weeks of treat-
ment, a blood sample was collected by venipuncture and
a 12-hour urine sample was collected. We thereby tested
the two hypotheses that firstly, early supplemental iron
intakes (2–4 mg/kg/d) result in oxidant stress, and that
secondly, incorporation of ingested iron is affected by
type of feed (human milk or formula) that the infant
receives.
Subjects and feedings
Eligibility required birth weight < 1500 g, < 34 weeks ges-
tation receiving oral or gastric feeds (75%), stable respira-
tory status as defined by FIO2 ≤ 30%, and a mean airway
pressure of 8 cm of water or less, if on assisted ventilation.
Infants were not eligible if they received transfusions
within the previous week or during the 4 week study
period, had any major congenital defect, liver disease,
necrotizing enterocolitis, grade III or IV intracranial hem-
orrhage or culture-proven sepsis.
All infants received parenteral nutrition with no added
iron before study entry. During the study, 3 infants
received formula (Similac Special Care, Ross Products
Division, Abbott Laboratories, Columbus, OH) and the
remaining 7 infants received their own mother's milk for-
tified with Enfamil Human Milk Fortifier (Mead Johnson
Nutritionals, Evansville, IN). No iron or vitamin supple-
mentation were given on the day of isotope administra-
tion, otherwise management of nutrition was under the
direction of the medical team.
Beginning at study entry, r-HuEPO (R.W. Johnson Phar-
maceutical Research Institute, Raritan, NJ) was adminis-
tered S.C. in a dose of 200 U/kg 3 times a week for six
weeks. Iron was given concomitantly in graded doses of 2
mg/kg/d wks 1 and 2 and 4 mg/kg/d, wks 3 and 4.
Administration of 57Fe and 58Fe test doses
At baseline (57Fe dosing) and again on d 14 (58Fe dosing)
each infant received one dose with a regular feed (as
described previously). A 24 hour equilibration time was
used and is sufficient to allow isotope to mix with nativePage 2 of 6
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milk at baseline was 148 ± 20 mL/kg and at week 2, 158 ±
18 mL/kg (x ± SD).
Enriched 57Fe (95 weight % 57Fe, Atomergix Inc.
Farmingdale, NY), and 58Fe (93.05 weight % 58Fe, Cam-
bridge Isotope Labs, Andover, MA) were converted to fer-
rous chloride as described previously [13]. Enriched
oxides were dissolved in a small amount of Aqua Regia
(HCl: HN03, 3:1), diluted, pH adjusted to 5 with NaOH,
brought up to a volume of 20 mL with saline and filtered
through a 0.2 um filter and stored in glass vials until use.
Before use, each vial was checked for purity from pyrogens
with a test kit (Limulus Ambeocyte Lysate Test Kit: Whit-
taker Bioproducts, Walkersville, MD).
To prepare the enriched formulas, an amount of solution
which provided approximately 1800 ug 57Fe/kg or 450 ug
58Fe/kg was added directly to the milk using a pre-weighed
syringe. 57Fe was equilibrated with vitamin C overnight in
milk alone. 58Fe was mixed in milk with vitamin C and a
solution of natural abundance ferrous sulfate (Fer-In-Sol,
Mead Johnson, Inc., Evansville, IN). The final iron con-
tent of the first feed with 57Fe was 0.2 mg/kg. The final
iron content of the latter feed was set to 4 mg/kg made up
from 58Fe, endogenous iron in the formula as labeled,
(human milk was considered to have negligible iron) with
the majority of iron from ferrous sulfate. This final dosage
matched the usual treatment dose (4 mg/kg/d) provided
with EPO at this time period. Milk administered by bottle
was flushed with 5 mL of a 10% glucose solution.
Laboratory methods
Hemoglobin (Hgb) concentration was determined in
whole blood by Coulter Counter (Coulter Electronics,
Inc., Hialeah, FL). Whole blood was centrifuged and
plasma removed. Red blood cells (RBCs) were washed 3
times in isotonic saline and both plasma and RBCs frozen
at -80°C until analysis.
For isotopic analyses, iron was obtained from RBCs
according to Fomon et al. [14]. Two week study periods
were used as 2 weeks is the time required for enrichment
of RBCs (14). For each of 10 infants, 3 separate samples
were analyzed for a total of 20 estimations of iron absorp-
tion, plus 10 baseline measurements. Briefly, after micro-
wave digestion with concentrated nitric acid (HNO3), in
closed vessels, iron was selectively extracted with xylene
that contained thenoyltrifluoroacetone and processed as
reported previously [15]. Samples were analysed for 58Fe/
54Fe and 57Fe/54Fe ratios by inductively coupled plasma
mass spectrometry (ICP-MS, Plasma Quad3, Thermo Ele-
mental, Franklin, MA US).
The quantity of administered 57Fe and 58Fe label incorpo-
rated into erythrocytes 14 days after each dose was calcu-
lated as described previously [14];
Total circulating iron was estimated as; Fe circ = BV * Hgb
* 3.47. BV is blood volume, assumed to be 0.085 L/kg
[16], Hgb is hemoglobin concentration in g/L, and 3.47 is
the mg/g concentration of iron in Hgb. The following
assumption was made; of the isotropic iron that is
absorbed, by 14 d, 80% is incorporated into erythrocytes
[14].
All glass and plastic beakers, flasks and pipettes were acid
washed and only distilled deionised water was used
throughout as previously reported [17]. Iron concentra-
tions were determined by atomic absorption spectrometry
(17). NIST standard reference material spectrophotomet-
ric grade iron was run as a reference standard and to deter-
mine a normalization factor applied to each sample. To
measure oxidant stress in plasma, malondialdehyde
(MDA) was measured by HPLC [18]. Total radical antioxi-
dant protection (TRAP) as a measure of the ability to resist
oxidative stress was measured using an oxygen electrode
(YSI Model 5331) according to Wayner et al. [19]. In
erythrocytes, superoxide dismutase (SOD) and catalase
(CAT) were determined spectrophotometrically [20,21].
F2-Iso-prostanes as a measure of oxidant stress in urine
were measured using a commercially available ELISA kits
(Oxford Biomedical Research Inc., Oxford, MI). Informa-
tion on oxygen exposure, medications, transfusions daily
nutrient intakes and other data was recorded from nursing
records.
Differences in descriptive data for study subjects were
assessed by Student's t tests (SPSS- version 10, SPSS Inc.,
Chicago, IL). Pearson Correlation Coefficients were deter-
mined between iron absorption and study weight, birth-
weight, gender and gestational age. Differences in iron
incorporation by type of feed and oxidative stress were
measured by both parametric and nonparametric tests
with consistent results.
Sample size was determined from measurements taken
from previous studies in similar infants (13, 17) based on
iron incorporation. We expected absorption in the F
group to be 10 % with an SD of 5 %. In the HM fed group
we expected absorption of 30% with an SD of 5 based on
our earlier work (13, 17). Thus with an expected differ-
ence of 20 %, a power of 0.8 and an alpha of 0.05 we
would need 5 subjects in each group. Significance for all
assays was assigned to p < 0.05 (two-tailed).
Results
Infants weighed 1046 ± 212 g at birth and were 28 ± 2
weeks gestational age (x ± SD: n = 10). All infants gainedPage 3 of 6
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period. For these infants: age at study entry was 35 ± 13
days (range 22–68 days); weight at study entry was 1363
± 217 g; week 2, 1708 ± 312 g; and week 4, 2167 ± 283 g.
HGB at baseline (87 ± 12 g/L) week 2 (89 v 11 g/L) and
week 4 (99 ± 12 g/L) increased significantly between
weeks 2 and 4. There was no difference in birth weight,
gestational age or weight at baseline between HM (n = 7)
fed infants and F (n = 3) fed infants.
Data for each subject is presented in Table 1. Incorpora-
tion into RBCs of 57Fe after the first 14 days of the study
period was 8.7 ± 5 % for HM fed infants and 8 ± 3 % for
F fed infants and did not differ. Incorporation of 58Fe from
days 14 to 28 of the study period into RBCs was 8.6 ± 5 %
for HM fed infants and 6.0 ± 2.7 % for F fed infants and
did not differ. Mean percent relative standard deviation
for all 30 samples including baseline that were analyzed
for isotopic enrichment was 0.62 ± 0.10 for 57Fe/54Fe
ratios and 0.77 ± 0.29% for 58Fe/54Fe ratios.
Energy and protein intake and volume of milk fed were at
base line; 103 ± 18 kcals/kg, 2.6 ± 0.6 g/kg and 139 ± 17
ml/kg. At week 2, energy intake was 134 = 30 kcal/kg, pro-
tein intake was 3.1 ± 0.7 g kg and volume of milk fed was
158 ± 10 ml/kg.
Data for plasma TRAP, MDA, urinary F-2-isoprostanes,
RBC SOD and CAT are presented in Table 1. As there was
no difference between feeding groups, data were pooled.
Control values for healthy adults and premature infants of
similar gestational ages not receiving EPO from our labo-
ratory are: for TRAP 964 ± 240, umol/L (adult, n = 23);
MDA 0.35 ± 0.17 umol/L (premature infant n = 36) 0.38
± 0.16 (adult, n = 13); urinary F2 isoprostanes 28 ± 13 ng/
mL (premature infant, n = 24); RBC SOD, 3.2 ± 1.8 U/ml
(premature infant, n = 33) 1.2 ± 0.3 (adult n = 10); RBC
CAT 68 ± 14 U/mL (premature infant, n = 30) 12 ± 20 u/
mL (adult, n = 20). As well, each infant at baseline served
as their own control for later analyses.
Measures of antioxidant status and oxidant stress did not
correlate with birth weight, gestational age, Apgar scores,
and volume of feed nor days of oxygen exposure.
Discussion
Iron isotopes
While our sample size is small (n = 10 infants), we were
able to obtain 3 measurements from each infant serving as
their own control. As well, the sample size is similar to iso-
tope studies reported in other infants (6, 10). We had
hoped to enrol at least 5 infants in each group as our
power analysis suggested, but this did not occur, thereby
increasing the chance of a Type II error. From this data, we
did not find any difference in incorporation of iron iso-
topes into RBCs between VLBW infants who were receiv-
ing either human milk or premature formula (Table 1). In
a previous experiment [13] we found that isotope incor-
poration could be affected by zinc intakes in these infants
in a non-meal situation. We chose however to examine
iron absorption as it would occur naturally in the NICU,
which is during the fed state. However, we are left too
speculate on the comparisons between feeding groups
because of the small sample size. We believe there is merit
in presenting this data as we originally hypothesized large
differences which clearly did not occur.
While it is known that food components can enhance iron
absorption, in general iron absorption decreases with
food intake [22]. In-between feedings iron absorption has
been shown to range from 32 to 42% exhibiting wide var-
iation [4,23,24]. With meals, absorption of stable and
radioactive iron isotopes has been reported to be from 2.8
to 15.3%, a range that our results fall within [4,25-27]. It
has been suggested that iron absorption by premature
infants is unregulated by the level of iron intake [4].
Fomon [14] found that the mean RBC Fe58 incorporation
was 7.8% for HM fed infants compared to 4.4% for for-
mula fed infants even when the isotope was fed between
meals. He suggested that his difference was due to the
greater quantities of inhibitors present in the intestine of
formula fed infants. Whether or not the assumed greater
Table 1: Oxidant status and iron incorporation in VLBW Infants during treatment with EPO plus iron
Baseline Week 2 Week 4
PLASMA TRAP (umol/L 492 ± 3451 510 ± 316 438 ± 293
PLASMA MDA (umol/L) 0.35 ± 0.47 0.33 ± 0.24 0.42 ± 0.48
URINE F2 -Isoprostanes (ng/mL) 19 ± 14 29 ± 30 30 ± 19
RBC SOD (U/mL) 3.1 ± 2 4.0 ± 2.3 3.8 ± 2.1
RBC CAT (U/mL) 62 ± 19 68 ± 25 75 ± 25
INCORP (%) ______ 8.5 ± 4.2 7.8 ± 4.4
1means ± S.D.Page 4 of 6
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lack of inhibitors present in formula feeding is still unre-
solved. This latter report was one of the studies that gen-
erated our hypothesis however; we did not find the same
results as Fomon [14] as we studied VLBW infants who
received 4 times the iron dose as did full-term infants in
the latter study. As well, Fomon [14] suggested that greater
iron incorporation into RBCs in HM fed infants made up
for lower Fe content in HM whereas in our study during
EPO treatment, the quantity of exogenous iron added to
feedings was so large as to mask any contribution from
milk feedings. The finding could also be a Type II error
due to the uneven sample size.
However the important finding in the current study is that
RBC incorporation of iron isotope does not appear to be
different in HM fed infants as compared to formula fed
infants in any significant way. Earlier reports suggest an
order of magnitude difference between HM and formula
fed infants (10, 11, 13) particularly in our earlier study
where one HM fed infants had an absorption of 35% of
the isotopic dose. Thus even the 1–2% possible difference
in our study that may have been found with a larger sam-
ple size does not indicate a concern for over absorption of
iron in HM fed premature infants when larger does of iron
are given with EPO therapy. Therefore concern of poten-
tial iron excess or increased free radical generation with
EPO plus iron in HM fed infants does not appear
warranted.
Oxidant stress
There has only been one study to date examining the
effects of EPO on potential free radical damage [9] in
VLBW infants and one report in adults [28]. Pollack [9]
reported a transient rise in MDA after intravenous iron
infusion. The present study with a more comprehensive
assessment did not find similar results either in MDA or F2
isoprostane levels. It is well known that iron may cause
oxidative damage however much of the data is from in
vitro assessment. As there is a substantial increase in iron
utilization during treatment with EPO, it may be that iron
is sequestered and not available for free radical chemistry
adults, EPO therapy was studied in hemodialysed patients
with and without iron [28]. EPO plus iron did not lead to
increased MDA levels however SOD, GHSPx and CAT
increased in this group of patients. In the present study,
we found a trend (p = 0.07) to increased CAT levels. The
authors in the latter study suggested that increased
enzyme activity levels might be due to an increased
number of reticulocytes or a stimulation of enzyme syn-
thesis in young RBC by reactive oxygen species. Differ-
ences in these latter studies may be due to different
populations and the much longer time of treatment (>6
months) in the adult population. In the current study,
lack of evidence of lipid peroxidation suggests that
increased CAT values are physiological and well within
the infants' ability to handle the current amounts of iron
given with EPO.
Recent work has also suggested that EPO plus early iron
does not affect anthropometry, need for rehospitilization,
transfusion after discharge nor developmental outcome
(29). Thus longer term data supports our short term data
that at least from the point of oxidative stress premature
infants can cope with early supplemental iron plus EPO.
Conclusion
a) When EPO therapy is used, particularly with iron
intakes up to 4 mg/kg/d, our data suggests that, in regards
to oxidative stress, the process appears to be safe.
b) Human milk feeding during early supplemental iron
during treatment with EPO does not enhance iron absorp-
tion. Increased iron absorption would have been a con-
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